BCL2L1 and plasma cell myeloma: Navas et al. [50] have reported that p38 MAPK inhibition enhances the cytotoxicity of bortezomib for multiple myeloma cells both by inhibiting the transient expression and phosphorylation of HSP27 and by down regulating Bclxl and Mcl-1 expression.